{
    "clinical_study": {
        "@rank": "94156", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 500mg deferiprone or placebo administered via intravenous infusion.\nFirst 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.\nNext 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.\nRandomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.\nSubjects enrolled to cohort 2 will receive an oral dose of deferiprone."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.\nRandomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.\nFirst 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.\nNext 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "Single center, randomized, double-blind, placebo-controlled, adaptive sequential\n      ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of\n      single doses of deferiprone administered by intravenous infusion to healthy males and\n      females. A bioavailability comparison will be included."
        }, 
        "brief_title": "A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          1. Healthy adult males or females, at least 18 years old but not older than 50 years.\n\n          2. Body weight at least 60kg.\n\n          3. Body Mass Index (BMI) \u2265 18.50 and \u2264 30.00 kg/m2\n\n          4. Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical history, ECG, vital signs, physical examination.\n\n          5. Non or ex-smoker (someone who has completely stopped smoking 6 months before study\n             start)\n\n          6. For females, negative result on a serum pregnancy test.\n\n        Main Exclusion Criteria:\n\n          1. Absolute neutrophil count (ANC) <1.5x10^9/L.\n\n          2. History or presence of hypersensitivity to deferiprone or any related products.\n\n          3. History or presence of gastrointestinal, liver or kidney disease, or any other\n             conditions known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs.\n\n          4. Presence of significant cardiovascular, pulmonary, hematologic, neurologic,\n             psychiatric, endocrine, immunologic or dermatologic disease.\n\n          5. Any history of tuberculosis (TB) or prophylaxis for TB.\n\n          6. Suicidal tendency, history of seizures, head trauma with coma or\n             craniotomy/trepanation, state of confusion or relevant psychiatric disease.\n\n          7. Inadequate venous access in either arm.\n\n          8. Presence of out-of-range cardiac interval or clinically significant ECG abnormalities\n             (PR <110 msec or > 220 msec, QRS <60 msec or >119 msec, QTcB > 450 msec for males and\n             >460 msec for females).\n\n          9. Use of acetaminophen, acetylsalicylic acid (ASA), or non-steroidal anti-inflammatory\n             drugs (NSAIDs) in the previous 7 days before study start.\n\n         10. Use of any enzyme-modifying drugs, including strong inhibitors of P450 (CYP) enzymes\n             such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole,\n             ketoconazole, diltiazem, and HIV antivirals OR strong inducers of CYP enzymes such\n             as: barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin, and St. John's\n             wart within 28 days prior to study start.\n\n         11. Maintenance therapy with any drug, or significant history of drug dependency or\n             alcohol abuse.\n\n         12. Had a clinically significant illness during the 28 days prior to study start.\n\n         13. Receipt of an investigational product in another clinical trial within 28 days prior\n             prior to study start.\n\n         14. Enrolment in a previous cohort of this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989455", 
            "org_study_id": "LA42-0113"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Deferiprone for infusion, 10mg/mL for intravenous infusion.\nOral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)", 
                "intervention_name": "Deferiprone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ferriprox", 
                    "DFP", 
                    "L1"
                ]
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Placebo: normal saline solution.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Saline solution."
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deferiprone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy", 
            "Deferiprone", 
            "DFP", 
            "L1"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mont-Royal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H3P3P1"
                }, 
                "name": "Algorithme Pharma Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single Center, Phase I, Double-blind, Placebo-controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Deferiprone Administered by Intravenous Infusion to Healthy Male and Female Volunteers", 
        "overall_official": {
            "affiliation": "ApoPharma Inc.", 
            "last_name": "Fernando Tricta, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The pharmacokinetic parameter, Tmax, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.", 
                "measure": "From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the time to reach maximum observed plasma concentration (Tmax) will be evaluated following intravenous administration of deferiprone or placebo.", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose."
            }, 
            {
                "description": "The pharmacokinetic parameter, Cmax, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.", 
                "measure": "From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the maximum observed plasma concentration (Cmax) will be evaluated following a single intravenous administration of deferiprone or placebo.", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion  and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose."
            }, 
            {
                "description": "The pharmacokinetic parameter, AUC, will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.", 
                "measure": "From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: area under the serum concentration time curve (AUC) will be evaluated following a single intravenous administration of deferiprone or placebo.", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose."
            }, 
            {
                "description": "The pharmacokinetic parameter, T1/2el will be assessed over a 14 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.", 
                "measure": "From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: the terminal elimination half-life (T1/2el) will be evaluated following a single intravenous administration of deferiprone or placebo.", 
                "safety_issue": "No", 
                "time_frame": "Pre-infusion and 0.17, 0.33, 0.5, 0.75 (collected during the intravenous infusion) and 1 (immediately after the end of intravenous infusion), 1.33, 1.67, 2, 2.5, 3,4,6,9,12 and 14 hours post-dose."
            }, 
            {
                "description": "Safety and tolerability will be evaluated through the assessment of adverse events (AEs), physical examination, vital signs, ECG, patient monitoring and laboratory tests.", 
                "measure": "Safety and tolerability of single ascending doses of deferiprone when administered by intravenous infusion in healthy volunteers.", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose, 0.5-24 hours post-dose and 5 days after dosing."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The pharmacokinetic parameter, AUC, will be assessed over a 24 hour interval using blood samples for analyses of deferiprone and its 3-O-glucuronide metabolite in healthy volunteers.The comparison between the oral and intravenous doses of deferiprone and deferiprone 3-O-glucuronide will be assessed to obtain an absolute bioavailability.", 
            "measure": "From serum deferiprone and deferiprone 3-O-glucuronide concentration time-profiles: area under the serum concentration time curve (AUC) will be evaluated following a single intravenous or oral administration of deferiprone.", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose to 24 hours post-dose."
        }, 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}